Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups,
compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous
immunotherapy in patients with mild to moderate asthma and allergic
rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house
dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen
Double blind, parallel placebo-controlled study. The subjects will receive medication during
hayfever, seasonal allergy, Perennial allergic rhinitis, House Dust Mite Allergy, pollen allergy, Allergic Rhinoconjunctivitis, Hay fever, Rhinitis, Allergic, Perennial
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.